A charter or agreement provision that penalizes existing preferred stockholders (often by converting their preferred to common) if they do not participate pro rata in a future down round.

Definition

A pay-to-play provision requires existing preferred stockholders to participate in a subsequent financing round (typically on a pro rata basis) or face an automatic penalty, most commonly forced conversion of their preferred stock into common stock, which strips them of liquidation preference, anti-dilution protection, and protective-provision voting rights. Pay-to-play mechanics are usually built into the certificate of incorporation so they apply automatically at the close of a qualifying future round, and they are most often negotiated during difficult financings (bridge rounds or down rounds) to ensure that all existing investors share in funding the company rather than free-riding on new or continuing investors' capital.

Why it matters

MedTech companies facing a regulatory delay, a failed trial endpoint, or a reimbursement setback sometimes need an emergency insider-led bridge or down round to survive to the next milestone. A pay-to-play provision incentivizes every existing investor to contribute new capital in that difficult moment; investors who decline are converted to common and lose their preferred rights, which reallocates effective ownership and control toward those who kept funding the company through the setback.

Common pitfalls

•Assuming a pay-to-play only affects investors who explicitly refuse; investors who are financially unable to fund their full pro rata share in a difficult round face the same automatic conversion penalty.
•Underestimating the signaling effect: a pay-to-play round can reveal to the market and to potential acquirers which investors have lost confidence, since non-participation is visible on the cap table.
•Structuring the conversion penalty ambiguously (for example, unclear on whether it applies per-series or per-investor), which invites disputes when the round closes.

Sources

NVCA Model Term Sheet · NVCA
Cornell LII: Preferred Stock · Cornell Law LII
SEC Investor.gov: Dilution · SEC Investor.gov

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.